Elevance Health Reports Strong Q3 2025 Results, Reaffirms Full-Year Outlook

Elevance Health, a major player in the health insurance industry, has reported robust financial results for the third quarter of 2025, surpassing Wall Street expectations and setting a positive tone for the upcoming earnings season in the healthcare sector.
Q3 Financial Highlights
Elevance Health posted a profit of $1.2 billion for the third quarter, marking a significant 17% increase from the $1 billion reported in Q3 2024. The company's revenues also saw substantial growth, reaching $50.7 billion, up 12.4% from $45.1 billion in the prior-year quarter.
These results exceeded analyst forecasts, as per Zacks Investment Research, leading to a rise in Elevance Health's shares during premarket trading. The strong performance also had a positive impact on the stock prices of some of the company's competitors.
Segment Performance and Key Drivers
The health benefits unit of Elevance Health reported operating revenue of $42.2 billion in Q3. This growth was attributed to higher premium yields, recent acquisitions, and expansion in the Medicare Advantage segment. However, the company's medical loss ratio stood at 91.3%, primarily due to ongoing cost trends in Medicare, with particular emphasis on Part D benefits affected by changes in the Inflation Reduction Act.
Elevance Health's Carelon division showed impressive growth, with operating revenue increasing by 33% year-over-year to $18.3 billion. This growth was driven by acquisitions in the home health and pharmacy sectors, as well as increased product revenue at CarelonRx.
Strategic Focus and Future Outlook
CEO Gail Boudreaux emphasized the company's focus on enhancing affordability and improving member experience through value-based care partnerships and AI-enabled digital solutions. She stated, "In a dynamic healthcare environment, we're focused on advancing affordability and elevating the member experience through our growing value-based care partnerships and AI-enabled digital solutions that simplify access and improve outcomes."
Despite a slight year-over-year decrease in total membership to 45.4 million, primarily due to lower Medicaid and Blue Card membership, Elevance Health has reaffirmed its 2025 outlook. The company expects to achieve $30 in earnings per share and maintain a full-year medical loss ratio of approximately 90%.
As the healthcare landscape continues to evolve, Elevance Health's strong Q3 performance and strategic initiatives position it well for sustainable growth and value creation in the coming years.
References
- Elevance Health shares rise premarket on Q3 earnings, revenue beat
Elevance Health kicked off another round of earnings reports for major insurers on Tuesday morning, posting double-digit year-over-year growth for both revenue and profits.
Explore Further
What factors contributed to the significant revenue growth of Elevance Health's Carelon division in Q3 2025?
How does Elevance Health's reaffirmed outlook for 2025 compare to its competitors in the health insurance industry?
What impact have the changes in the Inflation Reduction Act had on Elevance Health's Medicare Advantage and Part D benefits?
What specific AI-enabled digital solutions is Elevance Health implementing to simplify access and improve outcomes for its members?
How have Elevance Health's recent acquisitions influenced its performance and competitive positioning in the healthcare sector?